Author:
Répásy Balázs,Gazsó Tibor,Elmer Diána,Pónusz-Kovács Dalma,Kajos Fanni Luca,Csákvári Tímea,Kovács Bettina,Boncz Imre
Abstract
Abstract
Background
Generic competition is a vital health policy tool used in regulating the pharmaceutical market. Drug group HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase) inhibitors, widely known as “statins,” was the first drug group in Hungary in which generic prescriptions became mandatory. Our aim is to analyze the changes in the retail and wholesale margins through the generic competition regarding “statins”.
Methods
Data was derived from the nationwide pharmaceutical database of the Hungarian National Health Insurance Fund Administration, the only health care financing agency in Hungary. We observed the turnover data regarding the HMG-CoA-reductase inhibitor “statins” from 2010 through 2019. As the drugs under review have a fixed price point in Hungary, we effectively calculated the margins.
Results
In 2010, the consumer expenditure of statins was 30.7 billion HUF ($148 million), which decreased by 59%, to 12.5 billion HUF ($42.9 million) in 2019. In 2010, the annual health insurance reimbursement of statins was 23.7 billion HUF ($114 million), which underwent a 63% decrease to 8.6 billion HUF ($29.7 million) in 2019. In 2010, the DOT turnover was 287 million days, and it increased to above 346 million days for 2019, which reflects a 20% increase over the past nine years. The monthly retail margins decreased from 334 million HUF ($1.6 million), (January, 2010) to 176 million HUF ($0.61 million), (December, 2019). The monthly wholesale margins decreased from 96.3 million HUF ($0.46 million), (January, 2010) to 41.4 million HUF ($0.14 million), (December, 2019). The most significant downturn in margins was due to the introduction of the first two blind bids. The combined DOT turnover in reference to the examined 43 products consistently increased.
Conclusions
The decline in retail and wholesale margin and in health insurance expenditures was largely due to a reduction in the consumer price of generic medicines. DOT turnover of statins also increased significantly.
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Warraich HJ, Salami JA, Khera R, Valero-Elizondo J, Okunrintemi V, Nasir K. Trends in use and expenditures of brand-name atorvastatin after introduction of generic atorvastatin. JAMA Intern Med. 2018;178(5):719–21. https://doi.org/10.1001/jamainternmed.2018.0990.
2. Hornyák L, Nagy Z, Ilku L, Tálos Z, Endrei D, Ágoston I, Csákvári T, Danku N, Répásy B, Boncz I. Price competition and reimbursement of biosimilar granulocyte-colony stimulating factor in Hungary. Expert Rev Pharmacoecon Outcomes Res. 2019;14:1–7. https://doi.org/10.1080/14737167.2019.1582334.
3. Plans-Rubió P. The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices. Am J Cardiovasc Drugs. 2010;10(6):369–82.
4. Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the U.S. Pharmaceutical Industry, vol. 22(1991 Micr). Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution; 1991. p. 1–66 https://www.brookings.edu/bpea-articles/patent-expiration-entry-and-competition-in-the-u-s-pharmaceutical-industry/.
5. U.S. Food and Drug Administration. Generic Competition and Drug Prices. Secondary Generic Competition and Drug Prices, 2015. Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129385.htm. [Accessed 21 October, 2015.]